Clinical trial
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy…
NCT00054795 · Pharmacyclics LLC., Industry · Completed
Key facts
| NCT number | NCT00054795 |
|---|---|
| Title | Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART) |
| Official title | Randomized Phase III Trial of Xcytrin® (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer Undergoing Whole Brain Radiation Therapy |
| Lead sponsor | Pharmacyclics LLC., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | Motexafin Gadolinium |
| Enrollment | 550 |
| First posted | Feb 13, 2003 |
| Last update posted | May 8, 2007 |
| Countries | Australia, Austria, Belgium, Canada, France, Germany, Netherlands, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: